Media contact: Stéphanie Bardon – communication@genethon.fr – 01.69.47.12.78
June 28, 2021
Preliminary results of clinical trial for rare liver disease Crigler-Najjar syndrome presented at ESGCT congress
April 23, 2021
Genethon announces First Patient dosed in Clinical Trial of Investigational Gene therapy GNT 0004 for Duchenne Muscular Dystrophy
February 28, 2021
Genethon, 30 years of pioneering research and innovation in treating rare diseases
February 10, 2021
Genethon and WhiteLab Genomics join forces to enhance gene therapy through artificial intelligence
February 3, 2021
Genethon is delighted about the launch of a gene therapy clinical trial for late-onset Pompe disease
December 2, 2020
Genethon gets the green light from the ANSM to start an innovative gene therapy trial for Duchenne muscular dystrophy
September 21, 2020
Genethon welcomes the submission to EMA of Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)
GenSight Biologics, a french biopharma company, just submitted to EMAMarketing Autorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON), a rare, mitochondrial genetic disease, caused by mutation in the ND4 mitochondrial gene.
(read more)June 10, 2020
A Genethon team succeeds in inhibiting the immune response linked to AAV, opening up the possibility of treating more patients by gene therapy
January 30, 2020
Genethon welcomes the conclusive results of a gene therapy trial in Chronic Septic Granulomatosis, a rare disease of the immune system
January 9, 2020
Genethon strengthens its collaboration with Sarepta Therapeutics for the development of the gene therapy product GNT0004 in Duchenne muscular dystrophy
September 9, 2019
A gene therapy based clinical trial for Fanconi anemia patients offers its first successful results
June 26, 2019
First in vivo proof-of-concept in Steinert’s myotonic dystrophy, a neuromuscular disease
May 24, 2019
Towards a clinical trial for gamma-sarcoglycanopathy, limb-girdle muscular dystrophy
February 25, 2019
Clinical Proof-of-Concept Data for OTL-102 for the Treatment of X-CGD
December 10, 2018
